Spots Global Cancer Trial Database for Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Official Title: A Multicenter, Open Label, Phase I /Randomised Phase II Study to Evaluate Safety, Pharmacokinetics and Efficacy of BIBF 1120 in Comparison With Oral Sorafenib for Advanced Hepatocellular Carcinoma Patients.
Study ID: NCT01004003
Conditions
Study Description
Brief Summary: The study aim is to determine maximally tolerated dose (MTD) of BIBF 1120 in HCC (hepatocellular cancer) and compare efficacy of BIBF 1120 to Sorafenib in HCC patients
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
1199.37.43001 Boehringer Ingelheim Investigational Site, Wien, , Austria
1199.37.43002 Boehringer Ingelheim Investigational Site, Wien, , Austria
1199.37.33001 Boehringer Ingelheim Investigational Site, Paris, , France
1199.37.33002 Boehringer Ingelheim Investigational Site, Paris, , France
1199.37.49008 Boehringer Ingelheim Investigational Site, Berlin, , Germany
1199.37.49009 Boehringer Ingelheim Investigational Site, Erlangen, , Germany
1199.37.49002 Boehringer Ingelheim Investigational Site, Freiburg, , Germany
1199.37.49001 Boehringer Ingelheim Investigational Site, Hannover, , Germany
1199.37.49010 Boehringer Ingelheim Investigational Site, Heidelberg, , Germany
1199.37.49005 Boehringer Ingelheim Investigational Site, Jena, , Germany
1199.37.49004 Boehringer Ingelheim Investigational Site, Magdeburg, , Germany
1199.37.49003 Boehringer Ingelheim Investigational Site, München, , Germany
1199.37.49006 Boehringer Ingelheim Investigational Site, Tübingen, , Germany
1199.37.36001 Boehringer Ingelheim Investigational Site, Debrecen, , Hungary
1199.37.31002 Boehringer Ingelheim Investigational Site, Leiden, , Netherlands
1199.37.31001 Boehringer Ingelheim Investigational Site, Utrecht, , Netherlands
1199.37.48002 Boehringer Ingelheim Investigational Site, Olsztyn, , Poland
1199.37.48003 Boehringer Ingelheim Investigational Site, Warsaw, , Poland
1199.37.48001 Boehringer Ingelheim Investigational Site, Warszawa, , Poland
1199.37.40002 Boehringer Ingelheim Investigational Site, Bucharest, , Romania
1199.37.40003 Boehringer Ingelheim Investigational Site, Cluj-Napoca, , Romania
1199.37.44001 Boehringer Ingelheim Investigational Site, Edgbaston, Birmingham, , United Kingdom
1199.37.44005 Boehringer Ingelheim Investigational Site, Glasgow, , United Kingdom
1199.37.44008 Boehringer Ingelheim Investigational Site, Liverpool, , United Kingdom
1199.37.44002 Boehringer Ingelheim Investigational Site, London, , United Kingdom
1199.37.44003 Boehringer Ingelheim Investigational Site, London, , United Kingdom
1199.37.44006 Boehringer Ingelheim Investigational Site, Manchester, , United Kingdom
1199.37.44004 Boehringer Ingelheim Investigational Site, Nottingham, , United Kingdom
Contact Details
Name: Boehringer Ingelheim
Affiliation: Boehringer Ingelheim
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
